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Resumo
Introdução: A eletroconvulsivoterapia (ECT) é um tratamento seguro e eficaz, indicado para o tratamento de doenças 
mentais graves resistentes ao tratamento. No entanto, está associado a uma alta taxa de recaída após o término do curso 
de ECT agudos (ECT ‑A). É recomendado realizar tratamento de manutenção de forma a aumentar a taxa e duração 
da remissão. A ECT de manutenção (ECT ‑M) é uma opção, embora ainda pouco utilizada. O objetivo deste estudo 
foi avaliar a eficácia da ECT -M em reduzir o número e duração de hospitalizações, assim como custos associados, em 
doentes com doença mental grave. 
Métodos: Foi realizado um estudo em espelho comparando o número e duração de hospitalizações antes e após 
iniciação de ECT -M. Foram colhidas informações relativamente a dados demográficos e técnicos, assim como dose de 
medicação. Foi comparado o custo médio antes e após a iniciação de ECT ‑M. Todos os tratamentos foram realizados 
com uma MECTA spECTrum 5000QÒ. A análise estatística foi realizada com o SPSS 22. 
Resultados: Foram incluídos 16 doentes no estudo. O número médio de tratamentos de ECT ‑M eletroconvulsivoterapia 
foi 41, com uma duração média de 23 meses. A frequência mais comum foi mensal. Foi obtida uma diferença 
estatisticamente significativa quanto ao número de hospitalizações (Mdn= 2,0 antes e Mdn=0,0 após) e ao número 
total de dias em internamento (Mdn=86,0 antes e Mdn=14,5 após). Foram encontradas diferenças marginais na 
dosagem de antidepressivos, com valores superiores no período após iniciação e ECT ‑M. Não foram encontradas 
diferenças significativas na dosagem de antipsicóticos. O custo médio por doente, antes e após iniciação de ECT -M foi, 
respetivamente, 10 621€ e 5 653€. 
Conclusão: Na amostra estudada, a ECT -M reduziu significativamente o número de internamentos e dias de 
hospitalização. A iniciação de ECT ‑M reduziu o custo por doente em 47%.
Abstract
Introduction: Electroconvulsive therapy (ECT) is a safe and effective treatment for treatment resistant severe 
mental disorders. However, it has a high relapse rate, following the acute course (A ‑ECT). Maintenance treatment 
is recommended to increase remission rate and duration. Maintenance ECT (M ‑ECT) is an option, although under‑
‑prescribed. The aim of this study was to assess M ‑ECT effectiveness in reducing number and duration of hospital 
admissions, as well as associated costs, in patients with severe mental disorders. Mirror study comparing number and 
duration of hospital admissions before and after first M -ECT. 
Methods: Information was gathered for demographic and technical data, and drug dosing. Mean cost before and after 
the initiation of M ‑ECT was compared. All treatments were performed with a MECTA spECTrum 5000QÒ. Statistical 
analysis was performed using SPSS 22. 
Results: A total of 16 patients were enrolled. The mean number of M ‑ECT treatments was 41.25 with a mean duration 
of 23 months. Treatment frequency was mainly once a month. A statistically significant decrease was found for number 
of admissions (Mdn=2.0 before and Mdn=0.0 after) and for total days in admission (Mdn=86.0 before and Mdn=14.5 
after). Marginally significant results were found for antidepressive dosage, with higher dosages in the after initiation 
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period. No significant results were found for antipsychotic dosage variation. The mean cost per patient, before and after 
initiation of M ‑ECT, was respectively 10 621€ and 5 653€. 
Conclusão: In our sample, we found that M -ECT significantly reduces number of admissions and days in admission. 
Initiating M ‑ECT treatment decreased cost per patient by 47%.
Palavras ‑chave: Custo e Análise de Custo; Eletroconvulsivoterapia; Hospitalização; Perturbações Mentais/tratamento; 
Resultado de Tratamento; Tempo de Internamento
Keywords: Costs and Cost Analysis; Electroconvulsive Therapy;Length of Stay Mental Disorders/therapy; Patient 
Admission; Treatment Outcome
INTRODUCTION
Patients with severe mental disorders require treatment 
even after remission of the acute phase, in order to avoid 
relapses and a progressive functional deterioration. Elec‑
troconvulsive therapy (ECT)1 is an effective and safe2 ‑4 
treatment for severe mental disorders, most notably mood 
disorders5,6 and schizophrenia.3 However, the relapse 
rate is very high, with most recurrences occurring with‑
in the first 6 months after treatment.7 ‑9 Additional ECT 
sessions after acute electroconvulsive therapy (A ‑ECT) 
are successful in sustaining remission of symptoms over 
a long period of time10 ‑12 so maintenance electroconvul‑
sive therapy (M ‑ECT) is recommended for patients with 
treatment ‑resistant mental disorders13,14 and there are some 
guidelines on how and when to use it.1,15,16 ECT cost is 
a major concern which can limit its access, mainly when 
compared to other available treatments. In 2003, the Na‑
tional Institute for Clinical Excellence published an eco‑
nomic analysis not favourable to the use of ECT in several 
situations,17 including maintenance treatment, justified by 
lack of evidence on its effectiveness and also high risk for 
adverse effects, which was promptly criticized.18,19 Since 
then, other studies demonstrated the opposite view,16,20 
stating that M ‑ECT is effective and cost ‑effective as a third 
line option. However there are few studies that consider 
the cost ‑effectiveness of M ‑ECT. The present study has 
the potential to support the already existing evidence that 
M ‑ECT is a maintenance treatment option for patients who 
have had at least a response to a course of A ‑ECT. Thus, our 
aim is to demonstrate that M ‑ECT is an effective option for 
maintenance treatment in patients with severe mental dis‑
orders and to determine its long ‑term cost ‑effectiveness.
MATERIAL AND METHODS
a. Study design
Mirror ‑image studies (or pre ‑post design studies) are those 
in which outcomes are compared before and after a specif‑
ic event (eg. an intervention). A mirror study was designed 
to compare, in each patient, the number of hospital ad‑
missions and the total number of days as inpatients before 
and after the initiation of M ‑ECT. Accordingly, for each 
patient, 2 time intervals were used: between the initiation 
of M ‑ECT and 31st December 2018 (after initiation group), 
and the homologous period of time previous to the first 
M ‑ECT treatment (before initiation group). By general 
agreement, M ‑ECT refers to all treatments done after 
the first six months following A -ECT. All patients were 
at least 18 years when they started M ‑EC. An informed 
consent according to the Portuguese Mental Health Act 
and our Hospital’s procedure, was signed prior to the first 
treatment. Only patients who were on their first M -ECT 
programme were included, to prevent resampling from 
our first study.21 Patients were referred to ECT by their 
consultant psychiatrist, and evaluated by the main ECT 
practitioner before initiating an A ‑ECT course. Titration 
was done on the first session, according to electrode place‑
ment. After conclusion, the consultant psychiatrist and 
main ECT practitioner discussed criteria for initiation of 
M ‑ECT, which included adequate response to the A ‑ECT 
course and absence of adverse effects. 
b. Patient data
Variables such age, sex, main diagnosis, number of A ‑ECT 
and M ‑ECT, treatment duration, electrode placement, dos‑
age and M ‑ECT frequency were gathered. Patients were 
diagnosed by the referring psychiatrist, according to the 
International Classification of Diseases, revision 9 (ICD-
-9) classification system which is still officially used in 
our institution. Patients’ diagnoses were then grouped by 
major diagnostic categories using the International Classi‑
fication of Diseases, revision 10 diagnoses (ICD -10). Data 
was collected for antidepressant and antipsychotic dosing 
in each patient to evaluate changes during the M ‑ECT. 
Fluoxetine equivalent dose for antidepressants22 and olan‑
zapine equivalent dose for antipsychotics23,24 were chosen.
c. Cost calculation
The cost per day of an inpatient – excluding costs regarding 
diagnostic and therapeutic exams and medication  ‑ and the 
cost of an ECT treatment were analysed. A comparison 
was made between the mean cost of a patient before (cost 
per day x mean number of days in the ward) and after start 
M ‑ECT (cost per day x mean number of days in the ward 
+ cost per ECT treatment x mean number of A ‑ECT and 
M ‑ECT). For this, we used the database of our institution, 
the GDH (Homogenous Diagnostic Group), and the values 
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from our institution’s 2018 financial reports. We used 
mean values, as it more appropriate for cost calculation 
and policy making than medians.
d. Technical information
All patients were treated in our ECT unit using a 
constant ‑current (800 mA, 200 J) spECTrum 5000Q 
(MECTACORP, Portland, Oregon, USA), with the 2013 
software upgrade (ie, using the “Optimized Dosage” dos‑
ing tables).25 Unilateral treatments used 0.3 ‑millisecond 
ultra ‑brief pulses with doses 6 times above the seizure 
threshold, and bilateral treatments 1.0 ‑millisecond brief 
pulses with doses 2.5 times above the seizure threshold. 
Anaesthesia consisted of a combination of intravenous 
atropine (0.5 mg), thiopental (<6 mg/kg), and succinyl‑
choline (0.5 mg/kg).
e. Statistical analysis 
Performed under SPSS (version 22). Descriptive statistics 
were presented as means (M) and standard deviations (SD) 
for quantitative symmetrical variables and medians with 
interquartile ranges otherwise. For categorical variables, 
frequencies (n) and percentages were presented. Before 
and after initiation comparisons were performed with Wil‑
coxon rank test for asymmetrical variables. Paired samples 
t ‑test were used in case of normally distributed variables. 
Shapiro ‑Wilk test and histogram were used for this de‑
cision. Significance was considered for p<0.05. We also 
considered marginal significant differences for p<0.010 
when sample size was lower than 15.
RESULTS
a. Sample description
This study enrolled 9 (56%) men and 7 (44%) women in a 
total of 16 patients ranging from 22 to 76 years old (M=53; 
SD=16). The most frequent diagnosis were schizophrenia 
(ICD ‑10 F20) and mood disorders (ICD ‑10 F30 ‑F35). 
The number of A ‑ECTs varied between 5 and 15 and the 
number of M ‑ECTs varied between 11 and 192. Minimum 
and maximum treatment duration were 6 and 57 months. 
Frequency of M ‑ECTs was mostly once a month. Electro‑
de placement was mostly bilateral (BL) and the remaining 
were right unilateral (UL). Applied dosage ranged from 230 
mC to 1124 mC. Further information is provided in Table 1.
Table 1. Sample characteristics
Variable Statistic
Age (years) 53 (16)
Sex:
  Female 7 (44%)
  Male 9 (56%)
Main diagnosis:
  Schizophrenia 7 (44%)
  Schizoaffective disorder 2 (12%)
  Mood disorder 7 (44%)
Number of A ‑ECT 8.81 (3.26)
Number of M ‑ECT 41.25 (44.84)
Treatment duration (months) 23 (16)
Electrode placement:
  Right unilateral 2 (12%)
  Bilateral 14 (88%)
Dosage (mC) 572 (337)
Treatment frequency:
  Weekly 2 (12%)
  Fortnight 3 (19%)
  Monthly 11 (69%)
Results presented as M(SD) for quantitative and n(%) for categorical variables.
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b. Comparative analysis
Statistical differences were found for the number of ad‑
missions and days in admission, before and after M ‑ECT 
initiation. A reduction in median number of admissions 
and median days in hospital diminished was observed (Ta‑
ble 2). Also, marginally significant results were found for 
fluoxetine equivalence. No significant results were found 
for antipsychotic dosage variation (p= 0.280) (Table 3). 
Table 2. Admissions before and after initiation of M ‑ECT 
Before treatment After treatment
Wilcoxon Test
(p ‑value)
Number of admissions 2.0 (1,2 – 2,8) [1.0 – 8.0] 0.0 (0.0 – 1.0) [0.0 – 4.0] p=0.003
Days in admission 86.0 (75.0 – 118.0) [32.0 – 206.0] 14,5 (0.0 – 59.2) [0.0 – 112.0] p<0.001
Results presented as Mdn (P25 – P75) [min  ‑ max]
Table 3. Drug dosage before and after initiation of M ‑ECT 
Before initiation After initation
Wilcoxon Test 
(p ‑value)
Fluoxetine (n=9) (mg) 37 (28) 50 (27) p=0.053
Olanzapine (n=14) (mg) 10 (8) 12 (8) p=0.280
Results presented as M (SD)
c. Cost per patient 
The cost per inpatient per day, considering 2018 values, 
was 111€ (euros) and the cost of a single ECT treatment 
was 46€. The mean number days before and after initiation 
o M ‑ECT was 95.69 and 31.19, respectively. Therefore, 
the mean cost, per patient before and after the initiation 
of M ‑ECT was, respectively, 10 621€ and 5 653€. The 
financial burden with these patients is 47% less after they 
initiate M ‑ECT. We used means to calculate cost because 
it is more appropriate for policy making studies. However, 
using medians would be more statistically accurate, and 
the reduction in costs would be 66%. This values are only 
approximate as inflation was not considered. To this matter 
we accept that the increase in cost of hospitalization and 
ECTs is similar over time.
DISCUSSION 
a. Reducing readmissions
M -ECT significantly reduced the number of hospital ad‑
missions and the total days in admission within the same 
patient. All subjects had at least one admission (Mdn= 2.0) 
prior to M ‑ECT. After beginning M ‑ECT, only three pa‑
tients had further admissions. Number of hospital admis‑
sions was perceived as an outcome for relapses with severe 
symptoms. Although this is an indirect measure of clinical 
efficacy, these results support those of previous studies,26 ‑28 
that propose M ‑ECT as an effective maintenance treat‑
ment. The authors believe this study adds evidence to the 
existing literature, by demonstrating the effectiveness of 
M ‑ECT in diminishing hospital admissions (and its length) 
in a real ‑world set. Due to small sample size, which is a 
shared issue found in studies regarding M ‑ECT, we were 
not able to control for other variables such as electrode 
placement or main diagnosis.
b. Patient medication
At the beginning of M ‑ECT all patients were receiving at 
least one antipsychotic or antidepressant. Dosages of both 
these psychopharmacological categories increased (16% 
and 36%, respectively), though with no statistical signifi‑
cance. Therefore, these small differences are very unlikely 
to affect the main outcomes.
c. Cost of maintenance treatment with M ‑ECT 
The economic advantage of M ‑ECT as a maintenance 
treatment was evaluated. A reduction of almost 50% in 
cost with hospital admissions was observed after initia‑
tion of M ‑ECT. Most patients were undergoing M ‑ECT 
only once a month, so this cost reduction might be even 
superior in studies with a longer follow ‑up period. It is 
important to consider that we have a Beveridgian Nation‑
al Health Service in Portugal so these results can vary 
in countries with different Health Services and policies 
concerning ECT. Patients that start M ‑ECT have sig‑
nificantly less hospital admissions and spend less days 
in the ward which is also an indirect way of assessing 
functionality. Other studies display similar results which 
showed a significant decrease in cost of treatment after 
initiation of M ‑ECT,21,29,30 and that M ‑ECT can reduce 
treatment cost to less than a third.31 The authors question 
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the necessity for a revision on guidance on the use of 
electroconvulsive therapy by NICE. Since 2003, the evi‑
dence for recommendation of M ‑ECT as a cost ‑effective 
maintenance treatment as substantially grown, as this 
study add strength to that hypothesis. 
d. Study limitations
Mirror ‑image studies, although easy and inexpensive to 
develop, have inherent disadvantages such as regression 
to the mean, time period bias, lack of a control group, and 
asymmetrical treatment durations. This needs to be con‑
sidered when interpreting our findings. A selection bias 
must be considered, as only patients that had an adequate 
response to A ‑ECT underwent a M ‑ECT course, thus arti‑
ficially selecting patient with better prognosis. Although 
these results indirectly imply that the decrease in hospital 
admissions implies clinical improvement, psychometric 
evaluations were not applied to these patients. We pinpoint 
this as one of the biggest limitation of this study. Psycho‑
metric evaluations is now being routinely applied to all 
patients in our facility for future studies. Lastly, we did 
not calculate medication costs, which would make the cost 
analysis more accurate, even tough there were no signifi‑
cant differences between the two groups.
e. Future research
More studies in this area are needed in order to provide 
robust data for the creation of guidelines on the use of 
M ‑ECT in different mental disorders with emphasis in a 
more objective evaluation of clinical efficacy and long-
‑terms effects of M ‑ECT. 
CONCLUSION
In our sample, initiation of M ‑ECT after a course of A‑
-ECT significantly reduced the number of admissions and 
days in admission in the psychiatric ward. Increases in 
drug dosage were unlikely to affect this outcome. Further‑
more, initiating M ‑ECT treatment decreased cost by 47%. 
These results are in line with previous studies. 
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